Holen Sie sich die Stockscreener-App
8.62
3.79%
-0.34
Handel nachbörslich:
8.75
0.13
+1.51%
Schlusskurs vom Vortag:
$8.96
Offen:
$8.93
24-Stunden-Volumen:
1.45M
Relative Volume:
0.59
Marktkapitalisierung:
$851.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-18.34
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
-9.83%
1M Leistung:
-16.39%
6M Leistung:
-40.39%
1J Leistung:
-43.51%
1-Tages-Spanne:
$8.3184
$9.005
1-Wochen-Bereich:
$8.3184
$9.58
52-Wochen-Spanne:
$8.3184
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.62 | 885.48M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
UPDATE -- ARS Pharma to Present Real-World Data on - GlobeNewswire
ARS Pharma (Nasdaq: SPRY) to present real-world neffy data: 1 late-breaking oral, 6 posters - Stock Titan
What drives ARS Pharmaceuticals Inc stock priceFlag and Pennant Patterns & Learn to Think Like a Long-Term Investor - earlytimes.in
Can ARS Pharmaceuticals Inc. hit a new high this monthBreakout Watch & Daily Stock Trend Watchlist - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Intraday Action & Accurate Trade Setup Notifications - newser.com
Why ARS Pharmaceuticals Inc. stock could see breakout soon - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 20252025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
ARS Pharmaceuticals (NASDAQ: SPRY) to Host Q3 Results Webcast; Replay for 30 Days - Stock Titan
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results - Yahoo Finance
ARS Pharma Presents Late-Breaking Oral and Poster Sessions on Real-World Effectiveness of neffy® at ACAAI 2025 Annual Scientific Meeting - Quiver Quantitative
ARS Pharmaceuticals Inc. stock outlook for YEAR2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
ARS Pharma (Nasdaq: SPRY) shares 9 of 10 anaphylaxis cases treated with single-dose neffy - Stock Titan
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Weekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Investment Recap & Technical Pattern Based Signals - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this week2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockTrade Signal Summary & Expert Verified Stock Movement Alerts - newser.com
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Weekly Gains Report & Weekly Market Pulse Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Market Sentiment Report & Short-Term High Return Strategies - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsTrade Volume Summary & Growth Focused Investment Plans - newser.com
Published on: 2025-11-02 04:08:25 - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.Earnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityGap Up & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-01 01:27:58 - newser.com
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles - Markets Mojo
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment - MSN
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):